Literature DB >> 24689736

Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations.

Naoto Inoue1, Eisuke Takai, Tsutomu Arakawa, Kentaro Shiraki.   

Abstract

Unacceptably high viscosity is observed in high protein concentration formulations due to extremely large therapeutic dose of antibodies and volume restriction of subcutaneous route of administration. Here, we show that a protein aggregation suppressor, arginine hydrochloride (ArgHCl), specifically decreases viscosity of antibody formulations. The viscosities of bovine gamma globulin (BGG) solution at 250 mg/mL and human gamma globulin (HGG) solution at 292 mg/mL at a physiological pH were too high for subcutaneous injections, but decreased to an acceptable level (below 50 cP) in the presence of 1,000 mM ArgHCl. ArgHCl also decreased the viscosity of BGG solution at acidic and alkaline pHs. Interestingly, ArgHCl decreased the viscosity of antibody solutions (BGG, HGG, and human immunoglobulin G) but not globular protein solutions (α-amylase and α-chymotrypsin). These results indicate not only high potency of ArgHCl as an excipient to decrease the solution viscosity of high concentration antibodies formulations but also specific interactions between ArgHCl and antibodies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24689736     DOI: 10.1021/mp5000218

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  12 in total

1.  Viscosity Analysis of Dual Variable Domain Immunoglobulin Protein Solutions: Role of Size, Electroviscous Effect and Protein-Protein Interactions.

Authors:  Ashlesha S Raut; Devendra S Kalonia
Journal:  Pharm Res       Date:  2015-08-19       Impact factor: 4.200

Review 2.  Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development.

Authors:  Dheeraj S Tomar; Sandeep Kumar; Satish K Singh; Sumit Goswami; Li Li
Journal:  MAbs       Date:  2016-01-06       Impact factor: 5.857

3.  Contrasting the Influence of Cationic Amino Acids on the Viscosity and Stability of a Highly Concentrated Monoclonal Antibody.

Authors:  Barton J Dear; Jessica J Hung; Thomas M Truskett; Keith P Johnston
Journal:  Pharm Res       Date:  2016-11-11       Impact factor: 4.200

4.  Multiscale Coarse-Grained Approach to Investigate Self-Association of Antibodies.

Authors:  Saeed Izadi; Thomas W Patapoff; Benjamin T Walters
Journal:  Biophys J       Date:  2020-04-29       Impact factor: 4.033

5.  Droplet-Based Microfluidic Tool to Quantify Viscosity of Concentrating Protein Solutions.

Authors:  Deyu Yang; Maryam Daviran; Kelly M Schultz; Lynn M Walker
Journal:  Pharm Res       Date:  2021-10-18       Impact factor: 4.200

6.  Improving Viscosity and Stability of a Highly Concentrated Monoclonal Antibody Solution with Concentrated Proline.

Authors:  Jessica J Hung; Barton J Dear; Aileen K Dinin; Ameya U Borwankar; Sumarth K Mehta; Thomas T Truskett; Keith P Johnston
Journal:  Pharm Res       Date:  2018-04-30       Impact factor: 4.200

Review 7.  Viscosity Control of Protein Solution by Small Solutes: A Review.

Authors:  Taehun Hong; Kazuki Iwashita; Kentaro Shiraki
Journal:  Curr Protein Pept Sci       Date:  2018       Impact factor: 3.272

8.  Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies.

Authors:  Cholpon Tilegenova; Saeed Izadi; Jianping Yin; Christine S Huang; Jiansheng Wu; Diego Ellerman; Sarah G Hymowitz; Benjamin Walters; Cleo Salisbury; Paul J Carter
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

Review 9.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

10.  Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation.

Authors:  Jack E Bramham; Stephanie A Davies; Adrian Podmore; Alexander P Golovanov
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.